H.C. Wainwright Downgrades Esperion Therapeutics (ESPR) to Neutral
May 1, 2026 9:36 AM
H.C. Wainwright analyst Joseph Pantginis downgraded Esperion Therapeutics (NASDAQ: ESPR) from Buy to Neutral.The analyst comments "Downgrade to neutral on ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
